No profile data available.
Atara Biotherapeutics, Inc. (ATRA) is a healthcare company in the blood cancer treatment drugs industry, based in Thousand Oaks, United States, with about 10 full-time employees.
It reported revenue of $120.77 million for fiscal year 2025, down 6.3% from fiscal year 2024, and net income of $32.69 million. Its market capitalization was $95.16 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally.
Atara Biotherapeutics reported $120.77 million in revenue for fiscal year 2025, down 6.3% from $128.94 million in fiscal year 2024.
$95.16 million as of October 9, 2026.
Listed companies of a similar size in the same industry (blood cancer treatment drugs) include ADC Therapeutics SA (ADCT), Lyell Immunopharma, Inc. (LYEL), Cellectis S.a. (CLLS), Citius Oncology, Inc. (CTOR).